REGENERON PHARMACEUTICALS, INC. Contract Liability (Deferred Revenue)
REGENERON PHARMACEUTICALS, INC. (REGN) had Contract Liability (Deferred Revenue) of $684.80 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2026-07-30
- 2026-06-30: Contract with Customer, Liability, Current $684.80M.
- 2026-03-31: Contract with Customer, Liability, Current $636.20M.
- 2025-12-31: Contract with Customer, Liability, Current $553.00M.
- 2025-09-30: Contract with Customer, Liability, Current $545.60M.
| Period end | Contract with Customer, Liability, Current |
|---|---|
| 2026-06-30 | $684.80M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $636.20M 10-Q · filed 2026-04-29 |
| 2025-12-31 | $553.00M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $545.60M 10-Q · filed 2025-10-28 |
| 2025-06-30 | $481.90M 10-Q · filed 2025-08-01 |
| 2025-03-31 | $619.30M 10-Q · filed 2025-04-29 |
| 2024-12-31 | $627.70M 10-K · filed 2026-02-04 |
| 2024-09-30 | $627.20M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $586.00M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $516.70M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $458.90M 10-K · filed 2025-02-05 |
| 2023-09-30 | $417.30M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $381.10M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $426.30M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $477.90M 10-K · filed 2024-02-05 |
| 2022-09-30 | $547.20M 10-Q · filed 2022-11-03 |
| 2022-06-30 | $566.30M 10-Q · filed 2022-08-03 |
| 2022-03-31 | $491.30M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $442.00M 10-K · filed 2023-02-06 |
| 2021-09-30 | $507.80M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $520.00M 10-Q · filed 2021-08-05 |
| 2021-03-31 | $464.90M 10-Q · filed 2021-05-06 |
| 2020-12-31 | $577.70M 10-K · filed 2022-02-07 |
| 2019-12-31 | $591.70M 10-K · filed 2020-02-07 |
| 2018-12-31 | $452.50M 10-K · filed 2020-02-07 |
| 2017-12-31 | $320.10M 10-K · filed 2019-02-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |